Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT03196401
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT03174275
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 61
- Registration Number
- NCT03164772
- Locations
- 🇺🇸
Research Facility, Milwaukee, Wisconsin, United States
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1186
- Registration Number
- NCT03164616
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 35
- Registration Number
- NCT03162224
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 148
- Registration Number
- NCT03161223
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03158064
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Terence Friedlander, MD
- Registration Number
- NCT03150836
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 61
- Registration Number
- NCT03141359
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Columbia University
- Registration Number
- NCT03130764
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.